NO940084L - Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler - Google Patents

Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Info

Publication number
NO940084L
NO940084L NO940084A NO940084A NO940084L NO 940084 L NO940084 L NO 940084L NO 940084 A NO940084 A NO 940084A NO 940084 A NO940084 A NO 940084A NO 940084 L NO940084 L NO 940084L
Authority
NO
Norway
Prior art keywords
bdnf
molecules
members
neuron diseases
treating motor
Prior art date
Application number
NO940084A
Other languages
English (en)
Other versions
NO940084D0 (no
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of NO940084D0 publication Critical patent/NO940084D0/no
Publication of NO940084L publication Critical patent/NO940084L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Water Treatment By Sorption (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Fremgangsmåter for behandling av motor-neuron forstyrrelser, så som amyotroflsk lateral sklerose (Lou Gehrlgs sykdom) omfattende administrering til en pasient som trenger en slik behandling, en effektiv mengde av en neurotrofisk faktor som er et medlem av BDNF/NT-3/NGF familien av molekyler og som understøtter overlevelsen, veksten og/eller differensiering av motorneuroner, er beskrevet. Den er delvis basert på oppdagelsen av at BDNF og NT-3 hver kan ake cholin- acetyltransferase aktiviteten l motor-neuron kulturer. I en kombinasjon av BDNF eller NT-3 og et annet middel, så som CNTF kan bil anvendt for behandling av motor- neuron sykdommen. Fremgangsmåter for å fremme over- levelsen, veksten og/el]er differensieringen av motor- neuroner in vltro, fremgangsmåte for diagnostikk og analysesystemer som kan bli anvendt for å identifisere midler som har BDNF eller NT-3-1ignende aktivitet og som kan være nytt for behandling av motor-neuron sykdommer, er også beskrevet. Dyremodeller for motor- neuron sykdom produsert ved immunisering av dyr overfor BDNF/NT-3/NGF familiemedlemmer eller derivater derav eller ved administrering til dyrene anti-BDNF/Nt-3/NGF famile medlem anistoffer er også omtalt.
NO940084A 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler NO940084L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (2)

Publication Number Publication Date
NO940084D0 NO940084D0 (no) 1994-01-10
NO940084L true NO940084L (no) 1994-03-08

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940084A NO940084L (no) 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Country Status (20)

Country Link
EP (2) EP0593516B1 (no)
JP (1) JPH06509094A (no)
CN (1) CN1065768C (no)
AT (1) ATE202939T1 (no)
AU (2) AU675409B2 (no)
CA (1) CA2113083A1 (no)
DE (1) DE69231930T2 (no)
DK (1) DK0593516T3 (no)
ES (1) ES2157903T3 (no)
FI (1) FI940098A (no)
GR (1) GR3036776T3 (no)
HU (1) HUT70275A (no)
IE (1) IE921602A1 (no)
IL (1) IL101928A0 (no)
NO (1) NO940084L (no)
PT (1) PT100501A (no)
RU (1) RU94016525A (no)
SK (1) SK2694A3 (no)
WO (1) WO1993001300A1 (no)
ZA (1) ZA923639B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
ATE420656T1 (de) * 2000-05-05 2009-01-15 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
IN2014CN03629A (no) * 2004-11-17 2015-09-04 Neuralstem Inc
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
RU2473564C2 (ru) * 2007-08-10 2013-01-27 Ридженерон Фармасьютикалз, Инк. Антитела человека с высокой аффинностью к фактору роста нервов человека
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
AU675409B2 (en) 1997-02-06
WO1993001300A1 (en) 1993-01-21
NO940084D0 (no) 1994-01-10
EP0593516A1 (en) 1994-04-27
DE69231930T2 (de) 2002-04-11
GR3036776T3 (en) 2002-01-31
JPH06509094A (ja) 1994-10-13
FI940098A0 (fi) 1994-01-10
AU2009592A (en) 1993-02-11
FI940098A (fi) 1994-03-10
EP0593516B1 (en) 2001-07-11
IL101928A0 (en) 1992-12-30
HUT70275A (en) 1995-09-28
SK2694A3 (en) 1995-02-08
ATE202939T1 (de) 2001-07-15
PT100501A (pt) 1993-09-30
CN1065768C (zh) 2001-05-16
CN1071585A (zh) 1993-05-05
DK0593516T3 (da) 2001-09-17
EP0593516A4 (en) 1995-01-18
CA2113083A1 (en) 1993-01-21
EP0755682A1 (en) 1997-01-29
ES2157903T3 (es) 2001-09-01
IE921602A1 (en) 1993-01-13
HU9400063D0 (en) 1994-06-28
DE69231930D1 (de) 2001-08-16
AU7067696A (en) 1997-01-16
ZA923639B (en) 1993-02-24
RU94016525A (ru) 1996-06-10

Similar Documents

Publication Publication Date Title
NO940084L (no) Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler
Gatz et al. Psychological interventions with older adults.
GR3035001T3 (en) Nitric oxide donor composition and method for treatment of anal disorders
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
PH24026A (en) Method of treating multiple sclerosis with chalcone derivatives
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
PT84122A (fr) Procede pour la coloration de fibres keratiniques a 5,6 dihydroxyindole et du peroxyde d:hydrogene precede ou suivi d:un traitement par un iodure
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
FI943028A0 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
Avery et al. Bright dawn simulation compared with bright morning light in the treatment of winter depression
Gordon The relationship between language and behaviour.
NO944339D0 (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
Foa et al. Behavioral treatment of phobics and obsessive-compulsives.
Sweeney et al. Healing a child's spirit through play therapy: A scriptural approach to treating children.
Boyer Approaching cross-cultural psychotherapy.
Hoogduin et al. Double-Blind Research Psychotherapy
Sokolova On the problem of psychotherapy of borderline personality disorders
RU94006635A (ru) Способ коррекции функциональных состояний
Eletsky Effect of hemosorption on the time-course of neuropsychic disturbances in patients with psoriasis and neurodermatitis.
UA20012A (uk) Спосіб лікуваhhя постекстракційhої запальhої ексудативhої реакції у хворих hа катаракту
RU96117545A (ru) Способ лечения диабетической ретинопатии
Gauron et al. A married couple in separate therapy groups
Simon Plato on the Mind-Body Problem